S100B induces angiogenesis via the clathrin/FOXO1/β-catenin signaling pathway and contributes to Bevacizumab resistance in epithelial ovarian cancer
{{output}}
Introduction: Bevacizumab (BEV), the most common antiangiogenic agent for treating ovarian cancer, prolongs progression-free survival (PFS) but does not significantly improve overall survival (OS). Improving the limited clinical ... ...
